Menu

Johnson & Johnson JNJ

Full chart Compare
Set alert

Price alert · JNJ

All alert types
277.27 USD -3.51 (-1.25%)

Nov 11, 2026, 10:15 AM EST

276.67 Day range 278.66
193.83 52-week range 282.11
YTD
+33.98%
1 year
+43.05%
Market cap
667.79B
Revenue (ttm)
99.33B
Profit margin
16.20%
EPS (ttm)
6.59
Shares out
2.41B
P/E ratio
42.09
Forward P/E
24.16
Dividend
5.36 (1.94%)
Ex-dividend date
Nov 23, 2026
YTD return
+33.98%
1-year return
+43.05%
Volume
656.73K
Avg volume
7.00M
Open
277.96
Previous close
280.78
Day's range
276.67 – 278.66
52-week range
193.83 – 282.11
Beta
0.20
Analysts
Buy
Price target
279.41 (+0.8%)
Earnings date
Jan 26, 2027

5D +0.02 (+0.01%)

270275280ThuFriMonTueWed277.57

Key statistics

Enterprise value
706.55B
PEG ratio
3.11
Price / sales
6.80
Price / book
8.29
Dividend yield
1.90%
Payout ratio
80.12%
Revenue growth
5.90%
Free cash flow
18.50B
Total cash
17.23B
Total debt
44.65B
Return on equity
20.02%
Short % of float
0.78%
50-day average
266.07
200-day average
248.64

Financials — quick view

All financials
JNJ Revenue — quarterly 25.40B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
JNJ Net income — quarterly 210.00M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
JNJ EPS — quarterly 0.09
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

JNJ recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Jan 26, 2027Dec 27, 20262.91———
Oct 13, 2026Sep 27, 20262.522.59+0.07+2.78%
Jul 15, 2026Jun 28, 20262.852.90+0.05+1.75%
Apr 14, 2026Mar 29, 20262.682.70+0.02+0.75%
Jan 21, 2026Dec 28, 20252.462.460.000.00%
Oct 14, 2025Sep 28, 20252.762.80+0.04+1.45%

Upgrades / downgrades

JNJ analyst upgrades and downgrades
DateFirmActionFromTo
Oct 16, 2026Wells FargomainOverweightOverweight
Oct 15, 2026Morgan StanleymainOverweightOverweight
Oct 14, 2026Leerink PartnersmainOutperformOutperform
Oct 14, 2026Wells FargomainOverweightOverweight
Oct 14, 2026RBC CapitalmainOutperformOutperform
Oct 7, 2026GuggenheimreitBuyBuy

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Website
jnj.com

News

Your note

Sign in to keep a note on JNJ — it syncs with the Stock Master app.

Insider holders

JNJ insider holders
InsiderRelationLatest transactionDateShares held
BROADHURST VANESSAOfficerSaleJul 19, 202623,003
DECKER ROBERT JOfficerSaleFeb 26, 202624,462
DUATO JOAQUIN BOIXChief Executive OfficerSaleAug 12, 2026307,837
MULHOLLAND KRISTENOfficerConversion of Exercise of derivative securityFeb 12, 202619,830
REED JOHN COfficerConversion of Exercise of derivative securityApr 30, 202624,911
SCHMID TIMOTHYOfficerSaleSep 1, 202626,251

Institution ownership

JNJ institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.81%212,098,26459.55BJun 29, 2026
Vanguard Capital Management LLC6.53%157,226,37444.14BJun 29, 2026
State Street Corporation5.56%133,776,02537.56BJun 29, 2026
Geode Capital Management, LLC2.72%65,497,36318.39BSep 29, 2026
Vanguard Portfolio Management LLC2.67%64,370,81618.07BJun 29, 2026
JPMORGAN CHASE & CO2.42%58,301,60916.37BJun 29, 2026

Fund ownership

JNJ fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%76,421,62421.46BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%62,378,80217.51BJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%32,111,3909.02BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%31,318,9508.79BSep 29, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.24%29,810,7228.37BSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Value Index Fund0.95%22,911,0236.43BJun 29, 2026